Page 20 - RPIA_26-2

Alexandru Ciobanu, Joana Pita, Carlos Loureiro, Ana Todo-Bom

30. Zhang X, Simpson J, Powell H, Yang I, Upham J, Reynolds P, et al. steroidsensitive and steroid -insensitive asthma. Thorax 2015;
Full blood count parameters for the detection of asthma inflam- 70:458 -67.
matory phenotypes. Clin Exp Allergy 2014;44:1137 -45. 46. Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic
31. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. asthma. Cochrane Database Syst Rev 2015;15:CD002997.
2005;172:149 -60. 47. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithro-
32. Wilms EB, Touw DJ, Heijerman HG. Pharmacokinetics of azithro- mycin targets neutrophilic airway inflammation in refractory
mycin in plasma, blood, polymorphonuclear neutrophils and spu- asthma. Am J Respir Crit Care Med 2008;177:148 -55.
tum during long -term therapy in patients with cystic fibrosis. Ther 48. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck
Drug Monit 2006;28:219 -25. H, Ringoet V, et al. Azithromycin for prevention of exacerbations
33. Jaffé A, Bush A. Anti -inflammatory effects of macrolides in lung in severe asthma (AZISAST): A multicentre randomised double-
disease. Pediatr Pulmonol 2001;31:464 -73. -blind placebo -controlled trial. Thorax 2013;68:322 -9.
34. Cameron E, Mcsharry C, Chaudhuri R, Farrow S, Thomson N. 49. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB,
Long -term macrolide treatment of chronic inflammatory airway and the TELICAST Investigators. The effect of telithromycin in
diseases: risks, benefits and future developments. Clin Exp Aller- acute exacerbations of asthma. N Engl J Med 2006;354:1589 -600.
gy 2012;42:1302 -12. 50. Johnston SL. Azithromycin for Acute Exacerbations of Asthma:
35. Aghai ZH, Kode A, Saslow JG. Azithromycin suppresses activation The AZALEA Randomized Clinical Trial. JAMA Intern Med.
of nuclear factor -kappa B and synthesis of pro -infl ammatory 2016;176:1630 -7.
cytokines in tracheal aspirate cells from premature infants. Pediatr 51. Mandhane PJ, Paredes Zambrano de Silbernagel P, Aung YN,
Res 2007;62:483 -8. Williamson J, Lee BE, Spier S, et al. Treatment of preschool chil-
36. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, dren presenting to the emergency department with wheeze with
Zarogoulidis K. Macrolides: from in vitro anti -inflammatory and azithromycin: A placebo -controlled randomized trial. PLoS One.
immunomodulatory properties to clinical practice in respiratory 2017; 12(8):e0182411.
diseases. Eur J Clin Pharmacol 2012;68:479 -503. 52. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae
37. Good JT Jr, Rollins DR, Martin RJ. Macrolides in the treatment and Chlamydia pneumoniae in asthma: effect of clarithromycin.
of asthma. Curr Opin Pulm Med 2012;18:76 - 84. Chest 2002;121:1782 -8.
38. Beigelman A, Mikols CL, Gunsten SP, Cannon CL, Brody SL, 53. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link be-
Walter MJ. Azithromycin attenuates airway inflammation in a tween chronic asthma and chronic infection. J Allergy Clin Im-
mouse model of viral bronchiolitis. Respir Res 2010;30:90. munol 2001;107:595 -601.
39. Barker PM, Gillie DJ, Schechter MS, Rubin BK. Effect of macrolides 54. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E,
on in vivo ion transport across cystic fibrosis nasal epithelium. Boushey HA, et al., National Heart, Lung and Blood Institute’s.
Am J Respir Crit Care Med 2005;171:868 -71. Asthma Clinical Research Network. A trial of clarithromycin for
40. Sethi S, Murphy TF. Infection in the pathogenesis and course of the treatment of suboptimally controlled asthma. J Allergy Clin
chronic obstructive pulmonary disease. N Engl J Med Immunol 2010;126:747 -53.
2008;359:2355 -65. 55. Wong EH, Porter JD, Edwards MR, Johnston SL. The role of
41. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes macrolides in asthma: current evidence and future directions.
P, et al. A novel macrolide/fluoroketolide, solithromycin (CEM- The Lancet Respiratory Medicine 2014; 8: 657 -70.
-101), reverses corticosteroid insensitivity via phosphoinositide 56. Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ.
3 -kinase pathway inhibition. Br JPharmacol 2013;169:1024 -34. Refractory asthma: importance of bronchoscopy to identify phe-
42. Balloy V, Deveaux A, Lebeaux D, Tabary O, Le Rouzic P, Ghigo notypes and direct therapy. Chest 2012;141:599 -606.
J, et al. Azithromycin analogue CSY0073 attenuates lung inflam- 57. Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of
mation induced by LPS challenge. Br J Pharmacol 2014;171:1783 -94. Mycoplasma pneumoniae infection. Clin Microbiol Infect 2003;
43. Schögler A, Kopf B, Edwards M, Johnston S, Casaulta C, Kieninger 9:263 -73.
E, et al. Novel antiviral properties of azithromycin in cystic fibro- 58. Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld
sis airway epithelial cells. Eur Respir J 2015;45:428 -39. AR, et al. Trial of roxithromycin in subjects with asthma and se-
44. Hao M, Lin J, Shu J, Zhang X, Luo Q, Pan L, et al. Clarithromycin rological evidence of infection with Chlamydia pneumoniae. Am
might attenuate the airway inflammation of smoke -exposed asth- J Respir Crit Care Med 2001;164:536 -41.
matic mice via affecting HDAC2. J Thorac Dis 2015;7:1189 -97. 59. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithro-
45. Essilfie A, Horvat J, Kim R, Mayall J, Pinkerton J, Beckett E, et mycin and the risk of cardiovascular death. N Engl J Med
al. Macrolide therapy suppresses key features of experimental 2012;366:1881 -90.

96

REVIST A POR TUGUESA DE IMUNO ALERGOLOGIA